Introduction

The United Arab Emirates has become one of the most strategically important pharmaceutical markets in the Middle East. However, market access is strictly regulated, and no pharmaceutical product may be imported, marketed, or distributed without official registration approval from MOHAP.

Drug registration in the UAE is a structured, committee-driven process that requires regulatory precision, legalized documentation, and technical compliance aligned with international standards.

This guide outlines the full regulatory pathway from company setup to post-approval compliance.

1. Pre-Registration: Company & MAH Requirements

Before registering a product, the company must ensure:

• The Marketing Authorization Holder (MAH) is licensed in the UAE.
• The medical warehouse or marketing office holds a valid MOHAP license.
• Authorized users are registered in the MOHAP electronic portal.

Foreign manufacturers must appoint a UAE-based legal representative or establish a local entity.

Regulatory Insight: Many delays occur because companies attempt product registration before completing MAH licensing requirements.

2. Dossier Preparation: Building a Compliant File

The registration dossier must include:

• Administrative Documentation
• Application form (stamped and signed)
• Valid Free Sale Certificate (UAE Embassy attested)
• GMP certificate (valid and legalized)
• Agency agreement

Quality (CMC) Documentation

• API specifications
• Finished product specifications
• Manufacturing process summary
• Stability data (Zone IVb climate considerations)
• Batch analysis reports

Safety & Efficacy Data

• Bioequivalence studies (for generics)
• Clinical data (if applicable)
• Published literature references
• Labeling & Artwork
• Carton
• Blister
• Patient leaflet
• Arabic compliance considerations

Consistency between artwork and dossier is critical.

3. Electronic Submission via MOHAP Portal

The UAE drug registration process is fully digital.

Steps include:

1. Login through authorized credentials.
2. Select correct service classification.
3. Upload structured documentation.
4. Pay applicable government fees.
5. Track application status.

Incorrect service selection or misfiled documents may result in rejection before technical review.

4. Technical Evaluation & Committee Review

Once submitted, the file undergoes:

• Administrative screening
• Technical evaluation by specialized reviewers
• Pricing review (if applicable)
• Ministerial committee decision

Deficiency letters may be issued requiring clarification or additional documents.

Response timelines are critical. Delayed responses extend approval timelines significantly.

5. Pricing Approval

Drug pricing in the UAE is regulated.

• MOHAP considers:
• Country of origin price
• Reference country pricing
• CIF price calculations
• Distribution margins

Pricing submission must be accurate and supported by financial documentation.

6. Certificate Issuance & Validity

Upon approval:

• Registration certificate is issued.
• Validity: 5 years.
• Product can be legally imported and marketed.

7. Post-Approval Responsibilities

Registration is not the end of regulatory obligations.

MAH must:

• Report adverse events
• Submit variations before implementing changes
• Maintain valid GMP certification
• Apply for renewal before expiry

Conclusion

UAE drug registration requires structured planning, technical excellence, and regulatory foresight. Companies that approach it strategically avoid delays, financial loss, and market disruption.